SCHEMBL6703763

SCHEMBL6703763

O=C1c2cc(S(=O)(=O)Nc3cccc(O)c3)ccc2-c2ccc(S(=O)(=O)Nc3cccc(O)c3)cc21

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.65
HSD17B2 P37059 3/20 0.64
PKM P14618 4/20 0.63
MAPT P10636 3/20 0.63
KMT2A Q03164 3/20 0.63
SMN1; SMN2 Q16637 2/20 0.63
MEN1 O00255 2/20 0.63
HTT P42858 2/20 0.63
MAPK1 P28482 1/20 0.63
POLB P06746 2/20 0.61
UQCRB P14927 1/20 0.59
GAA P10253 2/20 0.57
PTPRC P08575 1/20 0.49
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
LMNA P02545 1/20 0.48
CYP19A1 P11511 1/20 0.47
HSD17B1 P14061 1/20 0.47
APEX1 P27695 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6702498 0.97 STAT3 (0.69) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6705029 0.97 STAT3 (0.69) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6705017 0.92 HTR6 (0.59) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6702482 0.89 STAT3 (0.56) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6701386 0.89 ALDH1A1 (0.57) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6703833 0.88 STAT3 (0.61) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6701392 0.87 STAT3 (0.57) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6701390 0.87 STAT3 (0.57) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6702181 0.86 HSD17B2 (0.58) STAT3HSD17B2PKMMAPTKMT2A
SCHEMBL6704050 0.86 AURKB (0.59) STAT3HSD17B2PKMMAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693136-B1 DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY ABBOTT LABORATORIES 2004-02-17 US claimed
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBVIE INC. 2004-01-29 US claimed
US-6693136-B1 DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY ABBOTT LABORATORIES 2004-02-17 US disclosed
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBVIE INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS P2RX3, P2RX1, P2RX2 STAT3 3398/4885HSD17B2 2678/4885PKM 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.